New Insights in the Skin Protective Activity of a Dexpanthenol Containing Formula (BEPANTHEN&amp;lt;sup&amp;gt;&amp;amp;#174;&amp;lt;/sup&amp;gt;) in a Diaper Rash-Like Model

Peltier, Erwan; Mekideche, Karim; Branka, Jean-Eric; Trapp, Sonja

doi:10.4236/jcdsa.2020.102008

Cited by 3 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over nine out of ten respondents reported that their babies experienced less nappy-related discomfort, crying, fidgeting and sleep disruption after applying the product. This correlates with previous clinical studies demonstrating that the application of dexpanthenol-containing products is associated with higher rates of alleviation of nappy rash symptoms, as well as significantly lower frequencies of nappy rash occurrence when compared with usual hygiene care alone [27,28]. Interestingly, a relatively higher proportion of as-needed users reported reductions in nappy-related discomfort, compared with frequent users.…”

Section: Discussionsupporting

confidence: 88%

“…The lipids mixture forms a lipophilic film on the skin surface that isolates the skin from irritants (urine and feces) and excess of moisture while replenishing the skin lipids. Water-in-oil preparation is considered by the experts as the preferred galenic formulation for IND preparations, it creates a barrier that is effective yet "breathable" [27]. By not being fully occlusive, it helps maintain healthy moisture levels in the skin.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Insights in Thailand on Usage Satisfaction and Perceived Efficacy of Dexpanthenol in Nappy Care

Tan¹,

Peltier

2020

Cosmetics

Self Cite

View full text Add to dashboard Cite

The prevalence of nappy rash or napkin dermatitis in Thailand infants aged 1–24 months is 36.1%. Dexpanthenol-containing nappy creams are clinical validated and effective in treating napkin dermatitis. This study explores the real-world usage satisfaction and perceived effectiveness of a 5% Dexpanthenol-containing product as a preventive strategy for napkin dermatitis. Respondents were mothers with babies between 6–12 months of age, who purchased and used a 5% Dexpanthenol-containing product (Bepanthen® Ointment) in the past one month. An online study collected respondents’ satisfaction with the product and its benefits and properties. A total of 300 respondents (52% frequent users and 48% as-needed users) completed the study. Over 90% of respondents reported that their babies experienced less nappy-related discomfort, crying, fidgeting and sleep disruption after applying the nappy care product. Almost all respondents (96%) were satisfied with the product. Notably, frequent users of the product reported higher rates of satisfaction than as-needed users (62% vs. 43%; p < 0.05). This high level of satisfaction was associated with the moisturizing properties and long-lasting skin protection provided by the dexpanthenol-containing product. Our findings from a real-world setting further validate the use of dexpanthenol-containing products as a preventive strategy for napkin dermatitis in Thai infants.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Real-World Insights in Thailand on Usage Satisfaction and Perceived Efficacy of Dexpanthenol in Nappy Care

Tan¹,

Peltier

2020

Cosmetics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The balm used in this study contains paraffin and petroleum jelly, which are both of hydrophobic character. Consequently, the ointment is able to hinder hydrophilic formulations and water-based solutions from spreading and prevents them from draining to the lower parts of the nasal cavity covered with respiratory mucosa ( Peltier et al, 2020 ). Other formulations such as water-based hydrogels would reduce the surface tension of the water-based drops at the tip of the catheter and, hence, could possibly drain to the rostral parts covered with respiratory mucosa.…”

Section: Discussionmentioning

confidence: 99%

Establishment of an Olfactory Region-specific Intranasal Delivery Technique in Mice to Target the Central Nervous System

et al. 2022

View full text Add to dashboard Cite

We have recently developed a region-specific catheter-based intranasal application method in mice by using CT scan-based 3D cast models of the murine nose (DOI: 10.2376/0005-9366-17,102). This technique is able to specifically deliver drugs to the olfactory region or to the respiratory region only. Thereby, intranasally administered drugs could be delivered either via neuronal connections to the central nervous system or via the well-perfused rostral parts of the nasal mucosa to the systemic circulation. In the present study, we transferred successfully this novel delivery technique to C57Bl/6 mice and determined parameters such as insertions depth of the catheter and maximum delivery volume in dependence to the weight of the mouse. Breathing was simulated to verify that the volume remains at the targeted area. A step-by-step procedure including a video is presented to adopt this technique for standardized and reproducible intranasal central nervous system (CNS) delivery studies (DOI: 10.3390/pharmaceutics13111904).

show abstract

“…Pantothenic acid is a constituent of coenzyme A, which catalyzes the synthesis of key components of the lipid layers of the skin that play a role in maintaining the skin's barrier function 17,19 . Topical dexpanthenol‐containing products have been shown to maintain and repair the skin barrier function, supporting the healing of skin and reducing inflammation, and to maintain hydration of the skin's outer layer, decreasing transepidermal water loss 4,19–22 …”

Section: Introductionmentioning

confidence: 99%

“…2,3 These irritants, in turn, disrupt the structure of the skin, leading to local inflammation. 3,4 IDD is characterized by reddening or scaling of the skin, which if untreated can progress to exudative or ulcerated lesions. [5][6][7] The condition can cause considerable discomfort to the baby, and can be distressing both to the infant, negatively impacting sleep and behavior, 8,9 and to the caregiver.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study

Peltier

Salvo

Ehret

et al. 2023

Health Science Reports

Self Cite

View full text Add to dashboard Cite

Background and Aims Irritant diaper dermatitis (IDD) is very common in infants and usually managed by the caregiver. Dexpanthenol‐containing ointment (DCO) is a decades‐long established product that has demonstrated efficacy and tolerability in the treatment and prevention of infant IDD in controlled clinical settings. The aim of this study was to evaluate the effectiveness of DCO in the treatment of infant IDD from the perspective of the caregiver by collecting data not explored in clinical trials, such as infant quality of life and the speed of action. Methods A retrospective observational real‐world data (RWD) study was conducted with French adult caregivers who had used a DCO to treat IDD in their infants within the past 6 months and consented to participate to the study completed a web‐based survey answering questions regarding the severity of their infants' symptoms (intensity/extent of redness and discomfort, rated using Likert scales) before and after DCO application. The speed of onset of symptom relief and product acceptability were also collected. Results A total of 500 caregivers of 564 infants completed the survey. Of these, 80% reported that DCO visibly treats IDD. In terms of speed of action, 83% declared that the first signs of symptom relief appeared after 1 day of application and 78% reported full symptom resolution within 2 days of application. Additionally, ≥77% of caregivers agreed that DCO provided overnight relief from the discomfort caused by IDD and reduced sleep disturbance in their children. Finally, 85% of caregivers declared being satisfied with the product overall and considered the product pleasant to use. Conclusion This evidence from caregivers' experience confirms that DCO can be considered an adequate medication to self‐manage IDD episode as it provides rapid relief of the signs and symptoms of inflammation, while by being pleasant to be use.

show abstract

New Insights in the Skin Protective Activity of a Dexpanthenol Containing Formula (BEPANTHEN<sup>&#174;</sup>) in a Diaper Rash-Like Model

Cited by 3 publications

References 15 publications

Real-World Insights in Thailand on Usage Satisfaction and Perceived Efficacy of Dexpanthenol in Nappy Care

Real-World Insights in Thailand on Usage Satisfaction and Perceived Efficacy of Dexpanthenol in Nappy Care

Establishment of an Olfactory Region-specific Intranasal Delivery Technique in Mice to Target the Central Nervous System

Evaluation of a 5% dexpanthenol‐containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver—A real‐world data observational study

Contact Info

Product

Resources

About